{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T19:47:03Z","timestamp":1649015223282},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T00:00:00Z","timestamp":1381449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00253-013-5284-0","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T16:58:12Z","timestamp":1381510692000},"page":"105-114","source":"Crossref","is-referenced-by-count":0,"title":["Construction and characterization of a novel chimeric antibody c3C7 specific for the integrin \u03b1IIb\u03b23 complex"],"prefix":"10.1007","volume":"98","author":[{"given":"Aiqin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,11]]},"reference":[{"key":"5284_CR1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0022-1759(87)90187-6","volume":"100","author":"JD Beatty","year":"1987","unstructured":"Beatty JD, Beatty BG, Vlahos WG (1987a) Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 100:173\u2013179","journal-title":"J Immunol Methods"},{"key":"5284_CR2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0022-1759(87)90186-4","volume":"100","author":"JD Beatty","year":"1987","unstructured":"Beatty JD, Beatty BG, Vlahos WG, Hill LR (1987b) Method of analysis of non-competitive enzyme immunoassays for antibody quantification. J Immunol Methods 100:161\u2013172","journal-title":"J Immunol Methods"},{"key":"5284_CR3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI109597","volume":"64","author":"JS Bennett","year":"1979","unstructured":"Bennett JS, Vilaire G (1979) Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 64:1393\u20131401","journal-title":"J Clin Invest"},{"key":"5284_CR4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/312643a0","volume":"312","author":"GL Boulianne","year":"1984","unstructured":"Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse\/human antibody. Nature 312:643\u2013646","journal-title":"Nature"},{"key":"5284_CR5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s12010-008-8434-6","volume":"157","author":"M Cao","year":"2009","unstructured":"Cao M, Cao P, Yan H, Lu W, Ren F, Hu Y, Zhang S (2009) Construction, purification, and characterization of anti-BAFF scFv-Fc fusion antibody expressed in CHO\/dhfr \u2212 cells. Appl Biochem Biotechnol 157:562\u2013574","journal-title":"Appl Biochem Biotechnol"},{"key":"5284_CR6","doi-asserted-by":"crossref","first-page":"25403","DOI":"10.1074\/jbc.M500462200","volume":"280","author":"P Chen","year":"2005","unstructured":"Chen P, Sun CX, Liu JN (2005) A novel anti-platelet monoclonal antibody (3C7) specific for the complex of integrin alpha IIb beta3 inhibits platelet aggregation and adhesion. J Biol Chem 280:25403\u201325408","journal-title":"J Biol Chem"},{"key":"5284_CR7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI111931","volume":"76","author":"BS Coller","year":"1985","unstructured":"Coller BS (1985) A new murine monoclonal antibody reports an activation-dependent change in the conformation and\/or microenvironment of the platelet glycoprotein IIb\/IIIa complex. J Clin Invest 76:101\u2013108","journal-title":"J Clin Invest"},{"key":"5284_CR8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1055\/s-0037-1615850","volume":"82","author":"BS Coller","year":"1999","unstructured":"Coller BS (1999a) Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost 82:326\u2013336","journal-title":"Thromb Haemost"},{"key":"5284_CR9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/hj.1999.v138.99078","volume":"138","author":"BS Coller","year":"1999","unstructured":"Coller BS (1999b) Potential non-glycoprotein IIb\/IIIa effects of abciximab. Am Heart J 138:S1\u2013S5","journal-title":"Am Heart J"},{"key":"5284_CR10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V68.3.783.783","volume":"68","author":"BS Coller","year":"1986","unstructured":"Coller BS, Folts JD, Scudder LE, Smith SR (1986) Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb\/IIIa receptor in an experimental animal model. Blood 68:783\u2013786","journal-title":"Blood"},{"key":"5284_CR11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1172\/JCI110973","volume":"72","author":"BS Coller","year":"1983","unstructured":"Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and\/or IIIa. J Clin Invest 72:325\u2013338","journal-title":"J Clin Invest"},{"key":"5284_CR12","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood.V66.6.1456.1456","volume":"66","author":"BS Coller","year":"1985","unstructured":"Coller BS, Scudder LE (1985) Inhibition of dog platelet function by in vivo infusion of F(ab\u2032)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb\/IIIa receptor. Blood 66:1456\u20131459","journal-title":"Blood"},{"key":"5284_CR13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1538-7836.2008.03251.x","volume":"7","author":"R Escher","year":"2009","unstructured":"Escher R, Cung T, Stutz M, Haeberli A, Djonov V, Berchtold P, Hlushchuk R (2009) Antiaggregatory and proangiogenic effects of a novel recombinant human dual specificity anti-integrin antibody. J Thromb Haemost 7:460\u2013469","journal-title":"J Thromb Haemost"},{"key":"5284_CR14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM198610163151602","volume":"315","author":"DJ Fitzgerald","year":"1986","unstructured":"Fitzgerald DJ, Roy L, Catella F, FitzGerald GA (1986) Platelet activation in unstable coronary disease. N Engl J Med 315:983\u2013989","journal-title":"N Engl J Med"},{"key":"5284_CR15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd1287","volume":"3","author":"J Graham","year":"2004","unstructured":"Graham J, Muhsin M, Kirkpatrick P (2004) Cetuximab. Nat Rev Drug Discov 3:549\u2013550","journal-title":"Nat Rev Drug Discov"},{"key":"5284_CR16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.med.54.101601.152136","volume":"54","author":"CW Hamm","year":"2003","unstructured":"Hamm CW (2003) Anti-integrin therapy. Annu Rev Med 54:425\u2013435","journal-title":"Annu Rev Med"},{"key":"5284_CR17","unstructured":"Hook KM, Bennett JS (2012) Glycoprotein IIb\/IIIa antagonists. Handb Exp Pharmacol (210):199\u2013223"},{"key":"5284_CR18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0290(19980405)58:1<73::AID-BIT8>3.0.CO;2-R","volume":"58","author":"SJ Kim","year":"1998","unstructured":"Kim SJ, Kim NS, Ryu CJ, Hong HJ, Lee GM (1998) Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng 58:73\u201384","journal-title":"Biotechnol Bioeng"},{"key":"5284_CR19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2165\/00003495-200868080-00001","volume":"68","author":"P Mandava","year":"2008","unstructured":"Mandava P, Thiagarajan P, Kent TA (2008) Glycoprotein IIb\/IIIa antagonists in acute ischaemic stroke: current status and future directions. Drugs 68:1019\u20131028","journal-title":"Drugs"},{"key":"5284_CR20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrd2957","volume":"9","author":"AD Michelson","year":"2010","unstructured":"Michelson AD (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9:154\u2013169","journal-title":"Nat Rev Drug Discov"},{"key":"5284_CR21","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","volume":"81","author":"SL Morrison","year":"1984","unstructured":"Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81:6851\u20136855","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5284_CR22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-006-9053-x","volume":"9","author":"MT Nakada","year":"2006","unstructured":"Nakada MT, Cao G, Sassoli PM, DeLisser HM (2006) c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model. Angiogenesis 9:171\u2013176","journal-title":"Angiogenesis"},{"key":"5284_CR23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","volume":"58","author":"SV Onrust","year":"1999","unstructured":"Onrust SV, Lamb HM, Balfour JA (1999) Rituximab. Drugs 58:79\u201388, discussion 89\u201390","journal-title":"Drugs"},{"key":"5284_CR24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003495-199957020-00006","volume":"57","author":"SV Onrust","year":"1999","unstructured":"Onrust SV, Wiseman LR (1999) Basiliximab. Drugs 57:207\u2013213, discussion 214","journal-title":"Drugs"},{"key":"5284_CR25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V64.1.59.59","volume":"64","author":"EI Peerschke","year":"1984","unstructured":"Peerschke EI, Coller BS (1984) A murine monoclonal antibody that blocks fibrinogen binding to normal platelets also inhibits fibrinogen interactions with chymotrypsin-treated platelets. Blood 64:59\u201363","journal-title":"Blood"},{"issue":"Suppl A","key":"5284_CR26","first-page":"19A","volume":"6","author":"JJ Popma","year":"1994","unstructured":"Popma JJ, Satler LF (1994) Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb\/IIIa receptor inhibition: the EPIC Trial results. J Invasive Cardiol 6(Suppl A):19A\u201328A, discussion 45A\u201350A","journal-title":"J Invasive Cardiol"},{"key":"5284_CR27","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398\u20131405","journal-title":"N Engl J Med"},{"key":"5284_CR28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1871525711311020003","volume":"11","author":"A Rognoni","year":"2013","unstructured":"Rognoni A, Lupi A, Cavallino C, Rosso R, Veia A, Bacchini S, Bongo AS (2013) Intracoronary injection of glycoprotein IIb\/IIIa, abciximab, as adjuvant therapy in primary coronary intervention. Cardiovasc Hematol Agents Med Chem 11:89\u201395","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"5284_CR29","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.V98.8.2432","volume":"98","author":"C Ruiz","year":"2001","unstructured":"Ruiz C, Liu CY, Sun QH, Sigaud-Fiks M, Fressinaud E, Muller JY, Nurden P, Nurden AT, Newman PJ, Valentin N (2001) A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb\u2013IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 98:2432\u20132441","journal-title":"Blood"},{"key":"5284_CR30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0049-3848(02)00207-4","volume":"107","author":"M Schwarz","year":"2002","unstructured":"Schwarz M, Nordt T, Bode C, Peter K (2002) The GP IIb\/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b\/CD18, alphaMbeta2). Thromb Res 107:121\u2013128","journal-title":"Thromb Res"},{"key":"5284_CR31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1538-7836.2009.03432.x","volume":"7","author":"HE Speich","year":"2009","unstructured":"Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK (2009) Variability of platelet aggregate dispersal with glycoprotein IIb\u2013IIIa antagonists eptifibatide and abciximab. J Thromb Haemost 7:983\u2013991","journal-title":"J Thromb Haemost"},{"key":"5284_CR32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.thromres.2007.11.003","volume":"122","author":"CX Sun","year":"2008","unstructured":"Sun CX, Chen P, Lu W, Liu JN (2008) Tyr178 of beta3 is critical for alphaIIb maturation and macromolecular ligand binding to alphaIIbbeta3. Thromb Res 122:203\u2013210","journal-title":"Thromb Res"},{"key":"5284_CR33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.coi.2008.05.013","volume":"20","author":"PG Swann","year":"2008","unstructured":"Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA (2008) Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 20:493\u2013499","journal-title":"Curr Opin Immunol"},{"key":"5284_CR34","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.CIR.98.11.1085","volume":"98","author":"SH Tam","year":"1998","unstructured":"Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998) Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb\/IIIa and alpha(v)beta3 integrins. Circulation 98:1085\u20131091","journal-title":"Circulation"},{"key":"5284_CR35","first-page":"37","volume":"112","author":"CL Wagner","year":"2003","unstructured":"Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, Damaraju L, Schaible T, Maini RN, Tcheng JE (2003) Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 112:37\u201353","journal-title":"Dev Biol (Basel)"},{"key":"5284_CR36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0022-1759(99)00184-2","volume":"233","author":"Z Wang","year":"2000","unstructured":"Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, Ratner D (2000) Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3\u2032 to 5\u2032 exonuclease activity. J Immunol Methods 233:167\u2013177","journal-title":"J Immunol Methods"},{"key":"5284_CR37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd3629","volume":"11","author":"A Younes","year":"2012","unstructured":"Younes A, Yasothan U, Kirkpatrick P (2012) Brentuximab vedotin. Nat Rev Drug Discov 11:19\u201320","journal-title":"Nat Rev Drug Discov"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-013-5284-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00253-013-5284-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-013-5284-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T18:37:27Z","timestamp":1596652647000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00253-013-5284-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,11]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["5284"],"URL":"https:\/\/doi.org\/10.1007\/s00253-013-5284-0","relation":{},"ISSN":["0175-7598","1432-0614"],"issn-type":[{"value":"0175-7598","type":"print"},{"value":"1432-0614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,11]]}}}